Zenith Epigenetics’ experienced research team has developed a cutting-edge epigenetic platform, generating differentiated, potent, and selective BET inhibitors. Our experienced management team and world-leading clinical collaborators are developing BETi combination therapies for multiple oncology indications. With a strong emphasis on translational medicine – for selecting patients that will benefit most from the therapy – Zenith is a leader in innovative clinical development of epigenetic combination therapies.
Our lead BETi, ZEN-3694, is in Phase 2 clinical development for the treatment of prostate cancer and breast cancer, the latter in collaboration with Pfizer.
Zenith Captial Corp. will hold its annual general meeting on January 15, 2025 at 1:00 PM (Calgary Time). The meeting will be held at the company's offices at 300, 4820 Richard Road SW, Calgary, Alberta. The comapny has organized a live webcast of the event and strongly encourages shareholders to attend the meeting virtually.
It is highly recommended that shareholders access the webcast over the internet using the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=xHIoxeIO
A replay of the webcast (using the same link provided) will be available for one month following the conclusion of the event.
Investors may also access the meeting by phone; dial 1-844-763-8274 (toll free within North America) or 1-647-484-8814. Callers should dial-in at least 15 min prior to the scheduled start time and ask to be joined into the Zenith Capital Corp. call.
Shareholders attending the meeting over the internet cannot vote at the meeting.
If you are a registered shareholder, please contact Computershare Investor Services Inc. at 1-800-564-6253 (toll free within North America) or 1-514-982-7555 to obtain your proxy form control number, which will allow you to cast your vote for the meeting online at www.investorvote.com by 1:00 PM (Calgary time) on January 13, 2025.
If you hold shares through an intermediary such as a brokerage firm, please contact your intermediary directly for a copy of the proxy form and instructions for voting.
Zenith Capital Corp. President & Chief Executive Officer, Donald McCaffrey, presented on the Emerging Growth Conference on September 25, 2024.
This live, interactive online event gave existing shareholders and the investment community the opportunity to interact with Mr. McCaffrey in real time.
You can watch a video of the presentation HERE
